Identifying Patient-Specific Tumor Targets

Video

Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, discussed the ATLAS platform and the TiTAN trial.

"ATLAS was created because we understood that you cannot predict yet what is going to be a good target for diverse human subjects. While predictions are quite good for certain subsets of people, it can't work well, in theory, for a whole population... We’re different because we use a biological assay to screen every single possible target to identify what the right target is for a person to be treated with.”

Genocea is creating personalized immunotherapies for patients with solid tumors with the help of their ATLAS platform. The platform uses patient samples to identify the best antigens to target in each patient’s tumors. The company’s 2 lead programs are GEN-009, a neoantigen vaccine, and GEN-011, a neoantigen-specific peripheral T-cell therapy. 

GEN-009 is being investigated in a phase 1/2 trial (NCT03633110) that has demonstrated long term, broad immune responses against neoantigens in data presented at the American Society of Clinical Oncology 2021 meeting in June. GEN-011 is being investigated in the phase 1/2 TiTAN trial (NCT04596033), which dosed its first patient in July 2021.

GeneTherapyLive spoke with Jessica Baker Flechtner, PhD, chief scientific officer, Genocea, to learn more about the ATLAS platform and the company’s focus on identifying the right targets for each patient. She also discussed GEN-011 and the TiTan trial.

REFERENCE
Genocea provides second quarter 2021 corporate update. News release. Genocea. July 29, 2021. https://ir.genocea.com/news-releases/news-release-details/genocea-provides-second-quarter-2021-corporate-update
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
© 2024 MJH Life Sciences

All rights reserved.